Table 2.
Primary and Secondary Outcomes According to mAb Treatment Status
| Outcome | mAb Treated | mAb Untreated | Adjusted OR | 95% CI |
|---|---|---|---|---|
| Overall sample size | n = 2,675 | n = 6,677 | … | … |
| All-cause hospitalization | ||||
| 28-day (primary outcome) | 108 (4.0) | 511 (7.7) | 0.48 | 0.38-0.60 |
| 90-day | 138 (5.2) | 590 (8.8) | 0.53 | 0.44-0.65 |
| All-cause mortality | ||||
| 28-day | 3 (0.1) | 63 (0.9) | 0.11 | 0.03-0.29 |
| 90-day | 6 (0.2) | 84 (1.3) | 0.17 | 0.06-0.35 |
| Any ED visit to day 28 | 501 (18.7) | 1,128 (16.9) | 1.24 | 1.09-1.40 |
| ED visit leading to hospitalization | 80/501 (16.0) | 424/1,128 (37.6) | 0.29 | 0.21-0.38 |
| Hospitalized sample size | n = 108 | n = 511 | … | … |
| Hospital LOS, mean ± SD, da | 5.8 ± 6.5 | 8.5 ± 9.8 | 0.64 | 0.51-0.82 |
| IMV or death | 5 (4.6) | 85 (16.6) | 0.22 | 0.07-0.52 |
| ICU admission | 13 (12.0) | 100 (19.6) | 0.52 | 0.26-0.97 |
| ICU LOS, mean ± SD, da | 3.5 ± 2.8 | 8.6 ± 9.9 | 0.22 | 0.10-0.48 |
Data are presented as No. (%) unless otherwise indicated. All regression models adjusted for age, sex, race/ethnicity, BMI, immunocompromised status, number of other comorbidities, insurance status, pandemic phase, and vaccination status. IMV = invasive mechanical ventilation; LOS = length of stay; mAb = monoclonal antibody.
a
Poisson regressions presented as adjusted incidence rate ratios with 95% CIs.